Screened 2026-09-10 · the tape above runs as of 15:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Alnylam Pharmaceuticals Inc holds its Markup at $247.51. The statistical read favours the sellers, held for 7 days.
As held on the ledger · 2026-09-10
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 7 days
Price at the screen
$247.51
Valuation
43.20 trailing · 19.85 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.30
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
25.74%
Below 33%
Interest-bearing debt is just 25.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
25.19%
Below 33%
Cash held in interest-bearing accounts and securities is 25.2% of assets, under the one-third limit.
Pass
Receivables
49.03%
Below 49%
Money owed to the company is 49.0% of assets, under the 49% limit.
Pass
Revenue purity
3.00%
Below 5%
Only 3.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-10 screen. The gold marker is the market price at the same screen. A 26.1% margin of safety to the base estimate.
Third-party analyst targets: 26 covering, consensus Buy. The average target sits +41% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-10 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Gene Silencing Drugs Face Narrow Moat Limits
Picture a treatment that turns off faulty genes before they trigger rare diseases. Alnylam has turned that idea into products such as ONPATTRO and AMVUTTRA, driving 96% revenue growth and a 90% return on equity. Yet the opportunity rating sits at none, so we pass despite a 35% gap between the $267 share price and our $360 fair value.
Forward earnings sit at 20 times, margins have reached 13%, and the narrow moat reflects real but limited protection in a crowded rare-disease field. Analyst targets cluster around $425 on a buy consensus, yet those forecasts rest on execution that remains unproven at scale.
The main risks are clinical setbacks, pricing pressure, and competition that could erode the current returns quickly. Currency and regulatory shifts add further volatility for a company still scaling commercial reach. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ALNY trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 19.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439.
2026-07-21Accumulation$267.47-5.4%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 5.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439.
2026-07-18Accumulation$282.85+0.0%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439.
2026-07-17Accumulation$282.85+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 3%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (25 analysts) rates it buy, with a mean price target of $439.
2026-07-03Accumulation$282.85+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$282.85Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
